Evaluation of Horizontal Ridge Augmentation Using 1% Metformin Gel and PRF in Split Crest Technique: A Randomized Controlled Clinical Trial
Abstract
Aim: To evaluate the efficacy of ridge splitting through the split crest method incorporating 1% metformin (MF) and platelet-rich fibrin (PRF) in comparison to the split crest technique (SCT) utilizing PRF alone.
Materials and methods: A total of 24 patients were recruited and randomly assigned to three distinct groups. Group I consisted of patients who underwent the SCT with implant placement alone. Group II included patients who received SCT with both implant placement and PRF, while group III comprised patients who experienced SCT with implant placement supplemented by a 1% MF gel combined with PRF. Clinical parameters, such as implant stability and crestal bone width, were measured for each implant immediately after insertion and again after a period of 6 months.
Results: The combination of MF and the PRF group exhibited the lowest level of crestal bone loss (CBL) relative to the other two groups. There was a notable increase in implant stability in both the control group and the study group (PRF + MF). Although there was also an increase in the PRF group, this change was not statistically significant.
Conclusion: This study indicates that, within its limitations, the concurrent application of 1% MF and PRF in ridge splitting procedures may lead to a reduction in CBL and an enhancement in implant stability.
Clinical significance: The introduction of a novel biomaterial has shown promise in enhancing the predictability of horizontal ridge augmentation procedures.…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 24 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.